Clinical Trial: Ustekinumab for Intestinal Behcet's Syndrome With Myelodysplastic Syndrome

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07582991) titled 'Ustekinumab for Intestinal Behcet's Syndrome With Myelodysplastic Syndrome' on April 23.

Brief Summary: Behcet's syndrome is a systemic vasculitis. Gastrointestinal involvement in Behcet's syndrome complicated by myelodysplastic syndrome represents a rare and severe subtype for which no standardized treatment guidelines currently exist, posing significant challenges in clinical practice. Ustekinumab, a biologic agent targeting IL-12/IL-23, has demonstrated favorable efficacy in both gastrointestinal Behcet's syndrome and inflammatory bowel disease. This study aims to evaluate the efficacy and safety of ustekinumab in patients with in...